Cutaneous reactions following COVID-19 vaccination assessed by dermatologists: a single-institutional study in Germany

J Dtsch Dermatol Ges. 2023 Mar;21(3):255-262. doi: 10.1111/ddg.14987. Epub 2023 Mar 9.

Abstract

Background and objectives: Cutaneous reactions following COVID-19 vaccination have been frequently described, whereas larger case series by dermatologists are lacking. This study assesses SARS-CoV-2 vaccination-associated skin reactions, severity, treatment, course, eliciting vaccines, allergy test results and tolerance to revaccination.

Patients and methods: Single-institutional, non-interventional study of dermatologists assessing cutaneous manifestations in 83 patients in Germany.

Results: 93 reactions were presented. Manifestations clustered into immediate (n = 51, 54.8%) and delayed hypersensitivity reactions (n = 10, 10.8%), chronic inflammatory skin diseases (n = 13, 14.0%), reactivation of latent herpes virus infection (pityriasis rosea/herpes zoster; n = 9; 9.7%) and others (n = 10, 10.8%). Vaccination was associated with new (76.3%) - mostly hypersensitivity reactions - or exacerbation of known skin diseases (23.7%), in this case predominantly chronic inflammatory skin diseases. Reactions occurred primarily within the first week (72.8%) and after first vaccination (62.0%). Treatment was required in 83.9% and hospitalization in 19.4%. In 48.8% revaccination led to recurrence of the same reactions. Disease was ongoing at last consultation in 22.6%, primarily in chronic inflammatory skin diseases. Allergy tests were performed in 15 patients (18.1%) and resulted negative.

Conclusions: It can be assumed that vaccination may trigger immune activation-related reactions especially in those patients predisposed to develop respective skin diseases.

Keywords: COVID-19 vaccination; cutaneous reactions; hypersensitivity reactions; urticaria.

MeSH terms

  • COVID-19 Vaccines* / adverse effects
  • COVID-19* / prevention & control
  • Dermatologists
  • Germany
  • Humans
  • Hypersensitivity*
  • SARS-CoV-2
  • Vaccination / adverse effects

Substances

  • COVID-19 Vaccines